Company Analysis
Sign in

Kiniksa Pharmaceuticals International, plc (KNSA)

Nasdaq: KNSA · Pharmaceutical Preparations · London · filing with the SEC since 2018
Full chart Alerts Compare
Grade7.2
◀ Past 7.8● Present 7.7▶ Future 5.7
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$678M+60.1%
Net income$59.0M+236.6%
Earnings per share$0.75+225.0%
Operating cash flow$138M+437.1%
Cash$166M-9.8%
Debtn/a
Shareholders’ equity$568M+29.5%
Shares, diluted79.0M+10.6%
Return on equity10.4%
The recordfrom its filings
Filings in 202693
Newest filingNov 12 · 4
Annual reportFeb 24, 2026
Quarterly reportOct 27, 2026
Next report due10-K by Mar 1
Insider sales, 12 months$122M
Insider buys, 12 months$0.00
Patents granted4
Filer categoryLarge accelerated filer
Trailing twelve months to Sep 2026Revenue $946MNet income $110MCash from operations $199Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
171819202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 12, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Nov 6, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Nov 3, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Nov 3, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Nov 3, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Nov 3, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Nov 3, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton KNSA · research, not advice